PMID- 37822726
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231018
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 10
DP  - 2023
TI  - Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial 
      Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable 
      Hepatocellular Carcinoma.
PG  - 1735-1748
LID - 10.2147/JHC.S431917 [doi]
AB  - BACKGROUND: The combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 
      antibodies with hepatic arterial infusion chemotherapy (HAIC) or transarterial 
      chemoembolization (TACE) has shown encouraging anti-tumor effects in the 
      treatment of hepatocellular carcinoma (HCC). We explored the efficacy and safety 
      of TKIs and anti-PD-1 antibodies combined with HAIC or TACE in HCC. METHODS: Data 
      from 302 HCC patients receiving HAIC combined with TKIs and anti-PD-1 antibodies 
      (HAIC-TP group) and 446 HCC patients receiving TACE combined with TKIs and 
      anti-PD-1 antibodies (TACE-TP group) were retrospectively collected. 
      Clinicopathological characteristics, tumor response, progression-free survival 
      (PFS), overall survival (OS), and adverse events (AEs) were compared between two 
      groups. Propensity score matching (PSM) analysis was performed to minimize bias. 
      RESULTS: The HAIC-TP group exhibited better objective response rate (RECIST: 
      33.1% versus 7.8%, P < 0.001; mRECIST: 51.4% versus 17.5%, P < 0.001), longer PFS 
      (12.4 months versus 8.2 months, P < 0.001), and longer OS (not reached versus 
      13.8 months, P < 0.001) than TACE-TP group. Surgery was performed after 
      combination therapy in 34 patients of the HAIC-TP group and in 7 patients of the 
      TACE-TP group (P < 0.001). Similar results were also observed in the PSM 
      analysis. Multivariate analysis indicated type of treatment, alpha-fetoprotein, 
      ALBI grade, portal vein tumor thrombus, and extrahepatic status were risk factors 
      for poor prognosis. Nausea, vomiting, diarrhea, and abdominal pain occurred more 
      frequently in the HAIC-TP group, whereas liver dysfunction occurred more 
      frequently in the TACE-TP group. All AEs were acceptable and manageable as a 
      result of treatment interruption or dose modification. CONCLUSION: The 
      combination of HAIC with TKIs and anti-PD-1 antibodies is an effective and safe 
      therapeutic regimen over TACE-based combination therapy for patients with HCC. A 
      prospective study with a large sample size is required to validate the efficacy 
      and safety of the combination therapy.
CI  - (c) 2023 Yu et al.
FAU - Yu, Bingran
AU  - Yu B
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
FAU - Zhang, Ning
AU  - Zhang N
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
FAU - Feng, Yun
AU  - Feng Y
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
FAU - Zhang, Yongfa
AU  - Zhang Y
AUID- ORCID: 0000-0002-3401-2400
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
FAU - Zhang, Ti
AU  - Zhang T
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20231006
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC10563810
OTO - NOTNLM
OT  - combination therapy
OT  - hepatic arterial infusion chemotherapy
OT  - hepatocellular carcinoma
OT  - transarterial chemoembolization
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/10/12 06:43
MHDA- 2023/10/12 06:44
PMCR- 2023/10/06
CRDT- 2023/10/12 04:09
PHST- 2023/08/24 00:00 [received]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2023/10/12 06:44 [medline]
PHST- 2023/10/12 06:43 [pubmed]
PHST- 2023/10/12 04:09 [entrez]
PHST- 2023/10/06 00:00 [pmc-release]
AID - 431917 [pii]
AID - 10.2147/JHC.S431917 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2023 Oct 6;10:1735-1748. doi: 10.2147/JHC.S431917. 
      eCollection 2023.